Medpace Holdings, Inc. $MEDP Shares Newly Acquired by MBL Wealth LLC

MBL Wealth LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 847 shares of the company’s stock, valued at approximately $529,000.

A number of other institutional investors have also recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its holdings in shares of Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock worth $10,615,000 after purchasing an additional 5,610 shares during the period. American Capital Management Inc. bought a new stake in Medpace in the second quarter worth $111,329,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Medpace during the 2nd quarter valued at about $1,685,000. Rice Hall James & Associates LLC acquired a new position in Medpace during the second quarter valued at approximately $28,659,000. Finally, Odyssean LLC acquired a new position in Medpace in the 2nd quarter valued at $3,369,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $669.20 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $684.52. The stock has a market cap of $18.68 billion, a P/E ratio of 37.10, a P/E/G ratio of 2.97 and a beta of 1.18. The firm has a 50 day moving average price of $611.66 and a 200 day moving average price of $537.67.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The business had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. During the same quarter last year, the business posted $3.86 EPS. The firm’s revenue was up 8.5% compared to the same quarter last year. Analysts predict that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO August Troendle sold 21,966 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total value of $13,739,074.02. Following the sale, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 336,140 shares of company stock worth $208,008,328 over the last ninety days. 20.50% of the stock is owned by corporate insiders.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
• Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
• Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
• Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
• Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
• Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MEDP. Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Truist Financial lifted their price objective on Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a report on Friday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, UBS Group increased their price objective on shares of Medpace from $673.00 to $700.00 and gave the stock a “neutral” rating in a report on Friday. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $642.91.

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.